| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Nervous System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Nervous System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Nervous System |
Recent Updates
Recently added Catalysts
Prothena Corporation plc$9.24
-0.4 (-4.15%)
C 47Pipeline Score Fair Value Biotech · Commercial
Market Cap
514.63 M
EPS
-2.81
P/E Ratio
-
Value Trade
5.28 M
SEC Financials
Q1 2026Dilution Risk
Revenue
51.08 M
R&D Expenses
12.63 M
Operating CF
28.88 M
Total Assets
349.89 M
Total Liabilities
37.28 M
Equity
312.62 M
D/E Ratio
12,345
1.03 %
Week
-8.04 %
1 Month
4.8 %
3 Month
-1.9 %
6 Month
-58.17 %
5 Year
21.36 %
All Time
Cash Data
Cash Position
329.46 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
505.13 K
52 Week Range
4.32 - 11.80
% held by Insiders
11.77 %
% held by Institutions
90.03 %
Enterprise Value
192.82 M
Total Shares
52.36 M
Short %
19.83 %
Float Shares
42.20 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Prothena Corporation plc
659Total events
9Upcoming
112Tier-1 (high impact)
2012 – 2029Coverage
Upcoming catalysts 9
Event history 650
May 7, 2026
▲Fast Track DesignationcoramitugDesignation
Fast Track designation for coramitug in ATTR-CM
ATTR amyloidosis with cardiomyopathysource ↗
May 7, 2026
▲Milestone PaymentcoramitugCorporate
$50 million clinical milestone payment from Novo Nordisk related to Phase 3 enrollment
ATTR amyloidosis with cardiomyopathysource ↗
May 7, 2026
◆Oral PresentationPrasinezumabPresentation
Oral presentation at AD/PD 2026: Modeling Parkinson's Disease Progression to Quantify Long-Term Treatment Effects via the Concept of Time Saved
Parkinson's diseasesource ↗
May 7, 2026
◆Poster PresentationPrasinezumabPresentation
Poster presentation at AD/PD 2026: Sustained Effect on Prasinezumab on Parkinson's Disease Motor Progression in the Open-Label Extension of the PASADENA Trial, 5-Year Update
Parkinson's diseasesource ↗
May 7, 2026
May 7, 2026
▲Fast Track DesignationBMS-986446Designation
Fast Track designation for BMS-986446 in Alzheimer's disease
Alzheimer's diseasesource ↗
May 7, 2026
▲Runway Guidance UpdateCorporate
Updated full year 2026 net cash used guidance to $18-$23 million (from $50-$55 million); expects year-end cash ~$273 million
May 7, 2026
Apr 28, 2026
▲Fast Track DesignationcoramitugDesignation
FDA grants Fast Track Designation for coramitug in ATTR-CM
ATTR amyloidosis with cardiomyopathysource ↗
Drug Pipeline Intelligence
C47
Pipeline Score $714M
Pipeline ValueFair Value
Valuation Signal6
Drugs Scored1.4x
rNPV / MCap Top 70%
Micro Cap (rank 274 of 911)
Percentile RankProthena Corporation plc carries a moderate pipeline score (47/100), with $1.8B risk-adjusted pipeline value, led by PRX003 in Psoriasis (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRX003 Small molecule | Psoriasis | Phase 1 | NCT02630901 | 20% | $796M | COMPLETED | 88 | - | - | Feb 28, 2018 | - | May 4, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
prasinezumab | Parkinson's disease | Phase 3 | 2026-03-23 | two years less advanced in disease severity five years after the start of the trial; estimated two years of ‘time saved’ Read More | Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026 Read More | |
prasinezumab | Parkinson's disease | Phase 3 | 2026-03-23 | two years less advanced in disease severity five years after the start of the trial; estimated two years of ‘time saved’ Read More | Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026 Read More | |
prasinezumab | Parkinson's disease | Phase 3 | 2026-03-23 | two years less advanced in disease severity five years after the start of the trial; estimated two years of ‘time saved’ Read More | Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PRTA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PRTA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PRTAProthena Reports First Quarter 2026 Financial Results and Business Highlights
Prothena Corporation plc reported strong financial results for Q1 2026, including a net income of $32.7 million, a significant improvement from the previous year's loss. The company highlighted positive developments in its partnered Phase 3 clinical programs, particularly for prasinezumab in Parkinson's disease and coramitug in ATTR-CM. Prothena also updated its financial guidance, projecting lower cash burn and an increase in cash reserves by year-end.
Read more →PRTA▼ -5.9%on this newsshared move
Prothena Reports First Quarter 2026 Financial Results and Business Highlights Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026 quarter-end cash and res
Prothena Corporation plc reported significant financial results for the first quarter of 2026, including a net income of $32.7 million, a considerable improvement from the previous year's net loss. The firm's cash position increased, with expectations to end the year with approximately $273 million in cash and equivalents. Prothena's collaboration with Novo Nordisk yielded a $50 million milestone payment following Fast Track designation for coramitug, and the company is engaged in multiple clinical trials with promising developments in Alzheimer’s and Parkinson’s treatments.
Read more →PRTAProthena to Report First Quarter 2026 Financial Results on May 7
Prothena Corporation plc has announced that it will report its first quarter 2026 financial results on May 7, 2026. The company will not hold a conference call following the release, consistent with its previous practices. Prothena is recognized for its expertise in protein dysregulation and is advancing a pipeline targeting various neurodegenerative diseases.
Read more →PRTA▲ +6.7%on this newsshared move
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena Corporation announced that the FDA has granted Fast Track Designation to coramitug, an investigational antibody for treating ATTR amyloidosis with cardiomyopathy. This designation aims to expedite the development of drugs addressing serious conditions. Coramitug is currently being evaluated in the Phase 3 CLEOPATTRA trial, which could significantly impact treatment options for this life-threatening disease.
Read more →PRTAProthena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
Prothena Corporation presented significant clinical updates on prasinezumab for Parkinson's disease and BMS-986446 for Alzheimer's disease at the AD/PD™ 2026 conference. Data indicated that prasinezumab may effectively slow disease progression, while BMS-986446 was found safe and well-tolerated in healthy participants. These findings support ongoing clinical studies for both treatments.
Read more →PRTA▲ +8.4%on this news
Prothena Announces up to $100 Million Share Repurchase Plan
Prothena Corporation plc has announced a share repurchase plan allowing for the buyback of up to $100 million of its ordinary shares. As of December 31, 2025, the company reported a strong cash position of $308.4 million with no debt. The plan is set to expire on December 31, 2026, and may be adjusted based on market conditions.
Read more →PRTAProthena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights Net cash used in operating and investing activities was $23.3 million and $163.7
Prothena Corporation plc reported its financial results for the fourth quarter and full year 2025, revealing a net loss of $244.1 million. The company is actively engaged in key clinical trials, including those for treatments in Parkinson's and Alzheimer's diseases. Prothena's cash position remains strong at $308.4 million, and it anticipates potential clinical milestone payments amounting to $105 million from its strategic partners in 2026. The report also notes significant restructuring and tax-related expenses that have impacted its overall financial performance.
Read more →PRTAProthena Reports Third Quarter 2025 Financial Results and Business Highlights Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine mo
Prothena Corporation plc announced its financial results for the third quarter of 2025, highlighting a cash position of $331.7 million amidst a net loss of $36.5 million. The company is advancing various clinical trials, including collaborations with Roche and Bristol Myers Squibb for treatments targeting Parkinson's and Alzheimer's diseases. Notably, Prothena has the potential to receive up to $105 million in clinical milestone payments related to ongoing collaborations. Despite challenges like reduced revenue and a significant net loss, Prothena's progress in drug development is promising.
Read more →PRTAProthena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program As previously communicated, Prothena plans to explore potential partnership interest to advance PRX012 and i
Prothena Corporation announced results from its Phase 1 ASCENT clinical program assessing PRX012 for Alzheimer's disease. The program demonstrated promising efficacy with significant reductions in amyloid plaque and generally well-tolerated treatment. However, the results also revealed a higher incidence of ARIA-E events compared to existing therapies. Prothena is considering partnerships to further develop PRX012 and its related compounds.
Read more →PRTA▲ +12.7%on this news
Prothena Announces that Novo Nordisk Will Advance Coramitug (formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy Coramitug is a potential first-in-class amyloid depleter antib
Prothena Corporation announced that Novo Nordisk will advance coramitug into Phase 3 development for ATTR amyloidosis with cardiomyopathy. This is a significant milestone, as coramitug is a potential first-in-class amyloid depleter antibody. The advancement is expected to address the unmet needs of patients who suffer from this disease. Prothena stands to earn up to $1.2 billion from the agreement, reflecting strong collaboration opportunities with Novo Nordisk.
Read more →PRTAProthena Reports Second Quarter 2025 Financial Results and Business Highlights Net cash used in operating and investing activities was $46.4 million in the second quarter and net cash used in operating and
Prothena Corporation plc reported its second quarter 2025 financial results, highlighting a net loss of $125.8 million with total revenues significantly down from the prior year. The company emphasized advancements in their pipeline, including the progression of prasinezumab into Phase 3 development for Parkinson's disease and anticipated initial data from PRX012 for Alzheimer's. Prothena also expressed potential financial benefits from upcoming clinical milestone payments but acknowledged significant restructuring charges related to program discontinuation. Overall, the financial outlook remains challenging amidst ongoing operational developments.
Read more →PRTA▲ +11.4%on this news
Prothena s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson s Disease Data from Phase IIb PADOVA study and longer term follow-up data suggest clinical benefit on to
Prothena Corporation plc and its partner Roche have announced the advancement of prasinezumab into Phase III development for early-stage Parkinson's disease. This decision follows positive data from the Phase IIb PADOVA study and open-label extensions. While prasinezumab showed potential clinical benefits, such as trends towards reduced motor progression, it missed the primary endpoint's statistical significance. Ongoing trials will further evaluate the drug's efficacy and safety over extended periods.
Read more →PRTAProthena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint Birtamimab did not meet the primary endpoint of time to all-cause mortality o
Prothena Corporation announced that its Phase 3 AFFIRM-AL clinical trial for birtamimab in AL amyloidosis patients did not meet the primary endpoint, leading to the decision to discontinue its development. Both primary and secondary endpoints were not met, raising concerns among stakeholders. Despite this setback, Prothena plans to focus on upcoming pipeline updates and further clinical trials, including those related to Alzheimer's disease. Plans for a workforce reduction and cost management have also been initiated in light of the trial results.
Read more →PRTAProthena Reports First Quarter 2025 Financial Results and Business Highlights Net cash used in operating and investing activities was $53.4 million in the first quarter of 2025 quarter-end cash and restrict
Prothena Corporation reported its financial results for Q1 2025, including a net loss of $60.2 million, an improvement from the previous year's loss. The company highlighted several upcoming clinical milestones, including topline results expected in 2Q 2025 from the Phase 3 AFFIRM-AL trial for birtamimab, and multiple readouts from the Phase 1 ASCENT trials for PRX012. Collaborations with Roche continue to showcase promising data for the treatment of early Parkinson's disease. Prothena maintains a strong cash position of $418.8 million while advancing its research and development pipeline in neurodegenerative diseases.
Read more →PRTAProthena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights Net cash used in operating and investing activities was $47.8 million in the fou
Prothena Corporation plc has reported its financial results for the fourth quarter and full year of 2024, showcasing a cash position of $472.2 million. The company anticipates significant advancements in its pipeline, including topline results for birtamimab in the Phase 3 AFFIRM-AL trial expected in Q2 2025. Additionally, it provided guidance indicating increased net cash use for 2025 while acknowledging risks related to partnered clinical trials. Prothena remains committed to developing treatments for neurodegenerative diseases, highlighting several promising projects in its portfolio.
Read more →PRTAProthena Reports Third Quarter 2024 Financial Results and Business Highlights Net cash used in operating and investing activities was $102.5 million and $102.5 million for the third quarter and first nine m
Prothena Corporation plc reported its financial results for the third quarter of 2024, including a net loss of $59.0 million. The company highlighted its strong pipeline for neurodegenerative diseases and rare peripheral amyloid diseases, with multiple clinical readouts expected starting in mid-2025. Collaborations with Roche and Bristol Myers Squibb, along with fast track designations from the FDA, underscore the potential of their investigational therapies. However, the company faces financial challenges, as indicated by their substantial quarterly cash burn.
Read more →PRTAProthena Reports Second Quarter 2024 Financial Results and Business Highlights Net cash provided by operating and investing activities was $15.8 million in the second quarter and net cash used by operating
Prothena Corporation plc announced its financial results for the second quarter of 2024, highlighting a strong cash position of $565.0 million and a significant improvement in revenues primarily due to collaboration with Bristol Myers Squibb. The company revealed an $80 million licensing agreement for PRX019, aiming to develop treatment solutions for neurodegenerative diseases. Prothena is actively engaged in multiple clinical trials, including those for Alzheimer's disease and AL amyloidosis, with important results expected within the next year. Despite challenges, the company is moving toward becoming a fully integrated commercial organization.
Read more →PRTAProthena Reports First Quarter 2024 Financial Results and Business Highlights Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024 quarter-end cash and restrict
Prothena Corporation plc reported its first quarter financial results for 2024, highlighting a net loss of $72.2 million, which is an increase from the previous year's loss. The company maintains a strong cash position of $548.7 million, and its Alzheimer's disease portfolio has received notable FDA designations, including Fast Track status for both PRX012 and PRX123. Clinical trials for these compounds are ongoing, signaling potential advancements in Alzheimer's treatment. Prothena also announced leadership changes, continuing its strategic growth amidst the challenges faced in the financial landscape.
Read more →PRTAProthena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights Net cash used in operating and investing activities was $52.6 million in the fou
Prothena Corporation plc reported its financial results for Q4 and the full year 2023, showcasing strong progress in advancing its pipeline of investigational therapeutics. The company expects to incur significant cash outflows in 2024 but maintains a robust cash position with $405 million projected by year-end. Key developments include FDA approvals for Fast Track designations of its Alzheimer's disease therapies and promising initial Phase 1 clinical trial data. Additionally, Prothena secured a $55 million milestone payment from Bristol Myers Squibb related to its drug collaborations.
Read more →PRTA▼ -13.2%on this news
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs Updates on PRX012 and PRX123 for treatment of Alzheimer s disease, and on birtamimab for treatment of AL amyloidosis Remain on
Prothena Corporation plc has provided business updates regarding its therapeutic pipeline, focusing on PRX012 and PRX123 for Alzheimer's disease, as well as birtamimab for the treatment of AL amyloidosis. Both PRX012 and birtamimab have received Fast Track Designation from the FDA, and the latter has shown promising survival benefits in clinical trials. The company reported a strong financial position with approximately $621 million in cash, enabling continued advancement of its clinical programs. Furthermore, Prothena's collaboration with Bristol Myers Squibb could yield additional financial incentives as development progresses.
Read more →PRTAProthena Reports Third Quarter 2023 Financial Results and Business Highlights Net cash provided by operating and investing activities was $9.1 million in the third quarter and net cash used in operating and
Prothena Corporation plc reported its financial results for the third quarter of 2023, revealing a net income of $21.9 million amidst a net loss of $79.6 million for the first nine months of the year. Significant progress was made in their clinical pipeline, including a $55 million payment from Bristol Myers Squibb for a licensing deal. Prothena is on track to deliver key clinical milestones for its neurological and amyloid treatment programs by the end of 2023 and into 2024. The company maintains a robust cash position of $673.1 million despite ongoing financial losses.
Read more →PRTAProthena Reports Second Quarter 2023 Financial Results and Business Highlights Net cash used in operating and investing activities was $45.7 million in the second quarter and $93.2 million for the first six
Prothena Corporation plc reported its second quarter 2023 financial results, indicating that net cash used for operating and investing activities was $45.7 million. The company increased its cash guidance for the year to approximately $600 million, augmented by successful presentations at the AAIC 2023 conferences on its Alzheimer's disease programs. They highlighted promising clinical trial results for birtamimab in AL amyloidosis, as well as partnerships with Bristol Myers Squibb and Roche to advance their drug development pipeline. Additionally, the company expects to file an IND for the dual-target vaccine PRX123 by the end of 2023.
Read more →PRTAProthena Reports First Quarter 2023 Financial Results and Business Highlights Net cash used in operating and investing activities was $47.5 million in the first quarter of 2023 quarter-end cash and restrict
Prothena Corporation plc reported its financial results for the first quarter of 2023, with a net loss of $46.9 million and cash reserves of $688.4 million. The company highlighted promising data for its Alzheimer's disease candidates, PRX012 and PRX005, which achieved significant milestones and received FDA designations. Despite an increase in research and development expenses, Prothena remains optimistic about progress in their drug pipeline, particularly in neurodegenerative disorders. Upcoming milestones include advancements in their ongoing clinical trials and collaborations.
Read more →PRTAProthena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights Net cash used in operating and investing activities was $5.1 million in the four
Prothena Corporation plc reported its fourth quarter and full-year 2022 financial results, highlighting a net loss of $116.9 million yet showcasing significant advancements in its Alzheimer's Disease portfolio. The company received FDA clearance for its PRX012 antibody and Fast Track designation, further indicating progress in its pipeline. Additionally, Prothena raised $172.4 million through a follow-on offering and secured a $40 million milestone payment from Novo Nordisk. The next 24 months are positioned as transformative for Prothena, with multiple clinical milestones anticipated.
Read more →PRTAProthena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004 NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy Prothena is eligible to receive dev
Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004 NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy Prothena is eligible to receive development and sales milestone payments from Novo Nordisk totaling up to $1
Read more →PRTAProthena Reports Third Quarter 2022 Financial Results and Business Highlights Net cash used in operating and investing activities was $31.3 million in the third quarter and $104.2 million for the first nine months of 202
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights Net cash used in operating and investing activities was $31.3 million in the third quarter and $104.2 million for the first nine months of 2022 quarter-end cash and restricted cash position was $497.0
Read more →PRTAProthena to Report Third Quarter 2022 Financial Results on November 3rd
DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third qu
Read more →PRTAProthena to Participate in Upcoming Healthcare Conferences
DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior mana
Read more →PRTAProthena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors
DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Helen S. Kim
Read more →PRTAProthena Reports Second Quarter 2022 Financial Results and Business Highlights Net cash used in operating and investing activities was $35.5 million in the second quarter and $72.9 million for the first six months of 202
Prothena Reports Second Quarter 2022 Financial Results and Business Highlights Net cash used in operating and investing activities was $35.5 million in the second quarter and $72.9 million for the first six months of 2022 quarter-end cash and restricted cash position was $510.1
Read more →PRTAProthena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that in connection with hi
Read more →PRTAProthena to Report Second Quarter 2022 Financial Results on August 8th
DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second q
Read more →PRTAProthena to Participate in Jefferies Healthcare Conference
DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior manag
Read more →PRTA▼ -7.2%on this news
Prothena Reports First Quarter 2022 Financial Results and Business Highlights Net cash used in operating and investing activities was $37.4 million in the first quarter quarter-end cash and restricted cash position was $
Prothena Reports First Quarter 2022 Financial Results and Business Highlights Net cash used in operating and investing activities was $37.4 million in the first quarter quarter-end cash and restricted cash position was $544.3 million Advanced PRX012, a potential best-in-class,
Read more →PRTA▲ +10.5%on this news
Prothena to Report First Quarter 2022 Financial Results on May 5th
DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first q
Read more →PRTA▼ -14%on this newsshared move
Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's Disease PRX012 is a potential best-in-class, subcutaneous anti-am
Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's Disease PRX012 is a potential best-in-class, subcutaneous anti-amyloid beta antibody therapy currently in a Phase 1 clinical
Read more →PRTAProthena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's Disease Prothena has initiated Phase 1 SAD study of PRX012, under investi
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's Disease Prothena has initiated Phase 1 SAD study of PRX012, under investigation for the treatment of Alzheimer's disease DUBLIN, Ir
Read more →PRTAProthena to Participate in Stifel 2022 Virtual CNS Days
DUBLIN, Ireland, March 21, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior mana
Read more →PRTA▲ +7.1%on this newsshared move
Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022
Oral presentation on preclinical data demonstrates Prothena’s dual Aβ/tau vaccine, for the potential treatment and prevention of Alzheimer’s, generated anti-Aβ and anti-tau antibodies to enable phagocytosis of Aβ and to neutralize tau Preclinical data from poster presentation de
Read more →PRTA▼ -5.9%on this news
Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights Net cash used in operating and investing activities was $22.8 million in the fourth quarter an
Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights Net cash used in operating and investing activities was $22.8 million in the fourth quarter and net cash provided by operating and investing activities w
Read more →PRTAProthena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022
DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth q
Read more →PRTAProthena to Participate in JMP Securities Hematology and Oncology Summit
DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior manag
Read more →PRTAProthena Reports Third Quarter 2021 Financial Results and Business Highlights Net cash provided by operating and investing activities was $111.9 million in the third quarter and $114.8 million for the first nine months o
Prothena Reports Third Quarter 2021 Financial Results and Business Highlights Net cash provided by operating and investing activities was $111.9 million in the third quarter and $114.8 million for the first nine months of 2021 Quarter-end cash and restricted cash position was $6
Read more →PRTAProthena to Report Third Quarter 2021 Financial Results on November 4th
DUBLIN, Ireland, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced today that it will report its third quarter an
Read more →PRTAProthena Announces Executive Appointments
DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that Chief Financial Officer Tran B. Ngu
Read more →PRTAProthena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that in connection with hiring a new em
Read more →PRTAProthena to Participate in Upcoming September Healthcare Conferences
DUBLIN, Ireland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team wi
Read more →PRTAProthena Reports Second Quarter 2021 Financial Results and Business Highlights Net cash provided by operating and investing activities was $36.6 million in the second quarter and $2.9 million for the first six months of
Prothena Reports Second Quarter 2021 Financial Results and Business Highlights Net cash provided by operating and investing activities was $36.6 million in the second quarter and $2.9 million for the first six months of 2021 quarter-end cash and restricted cash position of $402.
Read more →PRTA▼ -5.7%on this news
Prothena to Report Second Quarter 2021 Financial Results on August 5th
DUBLIN, Ireland, July 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second quarter a
Read more →PRTAProthena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021
Late-breaking PRX012 poster highlights significant ex vivo clearance of both pyroglutamate-modified and -unmodified Aβ plaque from AD brain at concentrations expected to be reached in CNS with subcutaneous administration Poster presentation demonstrates dual Aβ-tau vaccines simu
Read more →PRTAProthena to Present Data from Two of its Alzheimer’s Disease Programs at the Alzheimer’s Association International Conference 2021
DUBLIN, Ireland, July 20, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that it will present preclinical data on
Read more →PRTA▼ -8.2%on this news
Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme
Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars, including 100 million dollars in upfront and near-term clinical milestone payments Novo Nordisk will develop the phase 2 ready antibody PRX004 for the rare heart dise
Read more →PRTA▼ -8.2%on this news
more information, please visit the Company's website at www.prothena.com and follow the Company on Twitter ProthenaCorp. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headqua
Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena's ATTR Amyloidosis Programme Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars, including 100 million dollars in upfront and near-term clinical mil
Read more →PRTAProthena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
Prothena to receive $80 million from Bristol Myers Squibb for exclusive US license to PRX005; Next option for worldwide rights following completion of Phase 1 PRX005 is an investigational best-in-class anti-tau antibody targeting the microtubule binding region of tau for the tre
Read more →PRTAProthena to Participate in JMP Securities Life Sciences Conference on June 16
DUBLIN, Ireland, June 10, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team wil
Read more →PRTAProthena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors
DUBLIN, Ireland, May 20, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Sanjiv K. Patel, MBBS, MA, M
Read more →PRTAProthena Reports First Quarter 2021 Financial Results, and Provides Updated Financial Guidance and R D Update Net cash used in operating and investing activities was $33.7 million in the first quarter quarter-end cash an
Prothena Reports First Quarter 2021 Financial Results, and Provides Updated Financial Guidance and R D Update Net cash used in operating and investing activities was $33.7 million in the first quarter quarter-end cash and restricted cash position of $345.7 million provides fundi
Read more →PRTAProthena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease
DUBLIN, Ireland, May 10, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that the Company has earned a $60 million
Read more →PRTAProthena to Report First Quarter 2021 Financial Results on May 11th
DUBLIN, Ireland, May 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced tod
Read more →PRTAProthena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
Slowing of neuropathy progression for all 7 evaluable patients, evidenced by a +1.29 point mean change in NIS, was more favorable than expected progression of +9.2 points Improvement in neuropathy for 3 of these 7 evaluable patients demonstrated by a mean change in NIS of -3.33
Read more →PRTAProthena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021
DUBLIN, Ireland, April 15, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today annou
Read more →PRTAProthena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer
DUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today annou
Read more →PRTAProthena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares
DUBLIN, Ireland, March 24, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today annou
Read more →PRTAProthena Announces Proposed Offering of Ordinary Shares
DUBLIN, Ireland, March 23, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today annou
Read more →PRTAProthena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021
Superior profile of novel anti-tau antibody PRX005 supports advancement for the potential treatment of Alzheimer’s disease New analyses of prasinezumab continue to support potential disease modifying effect of prasinezumab in Parkinson’s disease; Roche expected to initiate Phase
Read more →PRTAProthena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer’s disease New pre-specified exploratory subgroup analyses and new digital biomarker data from Part 1 of the Phase 2 PASADENA study of prasinezumab in patients
Read more →PRTAProthena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R D Update Net cash used in operating and investing activities was $19.1 million in the fourth quarter and $80.6 m
Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R D Update Net cash used in operating and investing activities was $19.1 million in the fourth quarter and $80.6 million for the full year 2020 quarter-end cash and restrict
Read more →PRTAProthena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th
DUBLIN, Ireland, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced to
Read more →PRTAProthena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
Significant survival benefit observed in VITAL study for birtamimab-treated patients with AL amyloidosis at high risk for early mortality (Mayo Stage IV, HR=0.413, p=0.025, over 9 months) SPA agreement with FDA to enable registration of birtamimab at unprecedented p<0.10 for pri
Read more →PRTAProthena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis
Slowing of neuropathy progression for all 7 evaluable patients, evidenced by a +1.29 point mean change in NIS, was more favorable than expected progression of +9.2 points Improvement in neuropathy for 3 of these 7 evaluable patients demonstrated by a mean change in NIS of –3.33
Read more →PRTAProthena Reports Third Quarter 2020 Financial Results and Provides R D Update Net cash used in operating and investing activities was $19.5 million in the third quarter and $61.4 million for the first nine months of 2020
Prothena Reports Third Quarter 2020 Financial Results and Provides R D Update Net cash used in operating and investing activities was $19.5 million in the third quarter and $61.4 million for the first nine months of 2020 quarter-end cash and restricted cash position of $317.2 mi
Read more →PRTAProthena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020
Next generation anti-Aβ antibodies being developed for subcutaneous administration to improve access for patients with Alzheimer’s disease Multi-immunogen Aβ-tau vaccine being developed for the prevention and treatment of Alzheimer’s disease DUBLIN, Ireland, Nov. 04, 2020 (GLOB
Read more →PRTAProthena to Report Third Quarter 2020 Financial Results on November 4
DUBLIN, Ireland, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, anno
Read more →PRTARoche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson's Disease First anti-alpha-synuclein antibody to advance into confirmatory large study in patients with early Parkinson
Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson's Disease First anti-alpha-synuclein antibody to advance into confirmatory large study in patients with early Parkinson's disease expected to initiate in 2021 Prothena to earn a
Read more →PRTAProthena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress
DUBLIN, Ireland, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases will hold
Read more →PRTAProthena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15
DUBLIN, Ireland, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today an
Read more →PRTAProthena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders
DUBLIN, Ireland, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today an
Read more →PRTAProthena Reports Second Quarter 2020 Financial Results and Provides R D Update Net cash used in operating and investing activities was $18.7 million in the second quarter and $41.9 million for the first six months of 202
Prothena Reports Second Quarter 2020 Financial Results and Provides R D Update Net cash used in operating and investing activities was $18.7 million in the second quarter and $41.9 million for the first six months of 2020 quarter-end cash and restricted cash position of $336.6 m
Read more →PRTAProthena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders
Phase 2 PASADENA Part 1 study results selected as an oral Top Abstract DUBLIN, Ireland, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeuti
Read more →PRTAProthena to Report Second Quarter 2020 Financial Results on August 6
DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeleine of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, announce
Read more →PRTAProthena to Present at the Jefferies Virtual Healthcare Conference on June 3
DUBLIN, Ireland, May 27, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that members of its senior management team will present and participate in the Jefferies Virtual H
Read more →PRTAProthena Reports First Quarter 2020 Financial Results and Provides R&D Update and Updated Financial Guidance Net cash used in operating and investing activities was $23.2 million in the first quarter; quarter-end cash an
Prothena Reports First Quarter 2020 Financial Results and Provides R&D Update and Updated Financial Guidance DUBLIN, Ireland, May 6, 2020-- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today reported financia
Read more →PRTAProthena to Report First Quarter 2020 Financial Results on May 6
DUBLIN, Ireland, April 29, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its first quarter of 2020 financial results on Wednesday, May 6, 2020, after
Read more →PRTAProthena Provides Additional Information Regarding Upcoming Annual General Meeting of Shareholders in Response to COVID-19
DUBLIN, Ireland, April 24, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) today announced a change in the location of its annual general meeting of shareholder scheduled to be held on Tuesday, May 19, 2020. The meeting will convene as scheduled at The Merrion Hot
Read more →PRTAProthena Announces Appointment of Brandon Smith as Chief Business Officer
DUBLIN, Ireland, March 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced the appointment of Brandon Smith as Chief Business Officer. Mr. Smith will be responsible for le
Read more →PRTAProthena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update Net cash used in operating and investing activities was $14.6 million in the fourth quarter and $53.5 m
Prothena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update DUBLIN, Ireland, Feb. 12, 2020-- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today reporte
Read more →PRTAProthena to Report Fourth Quarter and Full Year 2019 Financial Results and Host Webcast Conference Call on February 12
DUBLIN, Ireland, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its fourth quarter and full year 2019 financial results on Wednesday, Februar
Read more →PRTAProthena Announces Appointment of Oleg Nodelman to its Board of Directors
DUBLIN, Ireland, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Oleg Nodelman to its Board of Directors. “Oleg is a veteran biotechnology investor and advisor with deep roots in
Read more →PRTAProthena Reports Third Quarter 2019 Financial Results and Provides R&D Update Net cash used in operating and investing activities was $9.2 million in the third quarter and $38.9 million for the first nine months of 2019;
Prothena Reports Third Quarter 2019 Financial Results and Provides R&D Update DUBLIN, Ireland, Nov. 5, 2019 -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported financial results for the third quarter and first nine months of 2019. In
Read more →PRTAProthena to Report Third Quarter 2019 Financial Results on November 5
DUBLIN, Ireland, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2019 on November 5, 2019 after the close of the U.S. financial markets.
Read more →PRTADear Colleagues, I'm writing to let you know that Wagner has decided to leave Prothena for personal reasons. His last day will be November 1. Many of us have worked alongside Wagner for more than a decade and have witnes
I'm writing to let you know that Wagner has decided to leave Prothena for personal reasons. His last day will be November 1. Many of us have worked alongside Wagner for more than a decade and have witnessed first-hand his passion for advancing new therapies for patients who suff
Read more →PRTAProthena Reports Second Quarter 2019 Financial Results and Provides R&D Update Net cash used in operating and investing activities was $12.2 million in the second quarter and $29.7 million for the first six months of 201
Prothena Reports Second Quarter 2019 Financial Results and Provides R&D Update DUBLIN, Ireland, August 6, 2019 -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported financial results for the second quarter and first six months of 2019.
Read more →PRTAProthena to Report Second Quarter 2019 Financial Results on August 6
DUBLIN, Ireland, July 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the second quarter and first six months of 2019 on August 6, 2019 after the close of the U.S. financial markets.
Read more →PRTAProthena Announces Appointment of Paula K. Cobb to its Board of Directors
DUBLIN, Ireland, July 01, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Paula Cobb to its Board of Directors. “As a biotechnology executive with wide-ranging global development, business
Read more →PRTAProthena to Participate in the Jefferies Healthcare Conference
DUBLIN, Ireland, May 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will present and participate in the Jefferies Healthcare Conference on June 6th at 10:30 AM
Read more →PRTAProthena Reports First Quarter 2019 Financial Results and Provides R&D Update Net cash used in operating and investing activities was $17.6 million in the first quarter; quarter-end cash and restricted cash position of $
Prothena Reports First Quarter 2019 Financial Results and Provides R&D Update DUBLIN, Ireland, May 7, 2019 -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported financial results for the first quarter of 2019. In addition, the Company p
Read more →PRTAProthena to Report First Quarter 2019 Financial Results on May 7
DUBLIN, Ireland, April 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, will announce financial results for the first quarter of 2019 on May 7, 2019 after the close of the U.S. financial markets. Consistent with past pra
Read more →PRTAProthena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis Results from final analysis of the composite primary endpoint were consistent with the futility analysis reporte
Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis DUBLIN, Ireland, April 18, 2019 -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported final results from the Phase 3 VITAL Amylo
Read more →PRTAProthena to Participate in Upcoming March Healthcare Conferences
DUBLIN, Ireland, March 05, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will present and participate in the following March investor conferences: Barclays Global
Read more →PRTAProthena Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Financial Guidance and R&D Update Net cash used in operating and investing activities was $22.5 million in the fourth quarter and $30.0 mi
Prothena Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Financial Guidance and R&D Update DUBLIN, Ireland, Feb. 14, 2019 - Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported financial results for the fourth qua
Read more →PRTAProthena to Report Fourth Quarter and Full Year 2018 Financial Results and Host Webcast Conference Call on February 14
DUBLIN, Ireland, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 14th, after the close of the U.S. fi
Read more →PRTAProthena Reports Third Quarter 2018 Financial Results and Provides R&D Update Net cash used in operating and investing activities was $33.7 million in the third quarter and $7.5 million in the first nine months of 2018;
Prothena Reports Third Quarter 2018 Financial Results and Provides R&D Update DUBLIN, Ireland - November 6, 2018 - Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported financial results for the third quarter and first nine months of 2018.
Read more →PRTAProthena to Report Third Quarter 2018 Financial Results on November 6
DUBLIN, Ireland, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2018 on November 6, 2018 after the close of the U.S. financial markets.
Read more →PRTAProthena Reports Second Quarter 2018 Financial Results and Provides R&D Update Net loss was $59.9 million in the second quarter and $108.6 million , for the first six months ended
Prothena Reports Second Quarter 2018 Financial Results and Provides R&D Update DUBLIN, Ireland - August 7, 2018 - Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported financial results for the second quarter and first six months of 2018.
Read more →PRTAProthena to Report Second Quarter 2018 Financial Results on August 7
DUBLIN, Ireland, July 31, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the second quarter and first six months of 2018 on August 7, 2018 after the close of the U.S. financial markets.
Read more →PRTAProthena Announces Appointment of Tran B. Nguyen as Chief Operating Officer
DUBLIN, Ireland, June 25, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience category, today announced that Tran B. Nguyen has been appointed to th
Read more →PRTAProthena Announces Phase 1b Clinical Trial Results of PRX002/RG7935 for Parkinson's Disease Published in JAMA Neurology
DUBLIN, Ireland, June 19, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience category, today announced that results from the Phase 1b multiple asce
Read more →PRTAProthena Announces Reorganization to Focus Resources on Advancing Neuroscience Pipeline
DUBLIN, Ireland, May 24, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience category, today announced that the Company has initiated a reorganizati
Read more →PRTAProthena Reports First Quarter 2018 Financial Results and Provides R&D Update Net cash used in operating and investing activities was $31.8 million in the first quarter; quarter-end cash and restricted cash position of $
Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update DUBLIN, Ireland - May 8, 2018 - Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience and orphan
Read more →PRTAProthena to Report First Quarter 2018 Financial Results on May 8
DUBLIN, Ireland, May 01, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience and orphan categories, will announce financial results for the first qu
Read more →PRTAProthena Discontinues Development of NEOD001 for AL Amyloidosis Phase 2b PRONTO study did not meet its primary or secondary endpoints Phase 3 VITAL Amyloidosis Study being discontinued based on futility analysis Investor
Prothena Discontinues Development of NEOD001 for AL Amyloidosis DUBLIN, Ireland, April 23, 2018 Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience and orphan categories,
Read more →PRTAProthena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases Prothena to receive a $100 million upfront payment and a $50 milli
Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases March 20, 2018 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery,
Read more →PRTAProthena to Present a Broad Range of Scientific and Health Outcomes Data at the 16th International Symposium on Amyloidosis
DUBLIN, Ireland, March 12, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that i
Read more →PRTAProthena to Participate in the Barclays Global Healthcare Conference
DUBLIN, Ireland, March 07, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that m
Read more →PRTAProthena Reports Fourth Quarter and Full Year 2017 Financial Results, and Provides Financial Guidance and R&D Update Net cash used in operating and investing activities was $39.9 million in the fourth quarter and $134.7
Prothena Reports Fourth Quarter and Full Year 2017 Financial Results, and Provides Financial Guidance and R&D Update DUBLIN, Ireland, Feb. 14, 2018 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and co
Read more →PRTAProthena to Participate in the Leerink Partners 7th Annual Global Healthcare Conference
DUBLIN, Ireland, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that me
Read more →PRTAProthena Announces Departure of Chief Medical Officer
DUBLIN, Ireland, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that Sarah Noonberg, MD, PhD, has d
Read more →PRTAProthena to Report Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 14
DUBLIN, Ireland, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quar
Read more →PRTAProthena to Participate in the 36th Annual J.P. Morgan Healthcare Conference
DUBLIN, Ireland, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that me
Read more →PRTAProthena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference
DUBLIN, Ireland, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan arenas, today announced that member
Read more →PRTAProthena Highlights Breadth of Novel Pipeline at R&D Day
Clinical development programs advancing toward key milestones Dr. Morie Gertz of Mayo Clinic discusses clinical aspects of AL amyloidosis and the role of cardiac biomarker NT-proBNP Novel discovery pipeline in neuroscience and orphan disease areas; highlights include tau and AL
Read more →PRTAProthena Reports Third Quarter 2017 Financial Results and Provides R&D Update Net cash used in operating and investing activities was $18.3 million in the third quarter and $94.8 million for the first nine months of 2017
Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update DUBLIN, Ireland - November 7, 2017 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein imm
Read more →PRTAProthena to Participate in the Credit Suisse 26th Annual Healthcare Conference
DUBLIN, Ireland, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior manageme
Read more →PRTAProthena to Report Third Quarter 2017 Financial Results on November 7
DUBLIN, Ireland, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the third quart
Read more →PRTAProthena Reports Results from Phase 1b Multiple Ascending Dose Study of PRX003 in Patients with Psoriasis Data demonstrated consistent safety, tolerability and pharmacodynamic effects as previously reported from Phase 1a
Prothena Reports Results from Phase 1b Multiple Ascending Dose Study of PRX003 in Patients with Psoriasis DUBLIN, Ireland, September 28, 2017- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercial
Read more →PRTAProthena Presents New Research Supporting Clinical Relevance of Cardiac Biomarker NT-proBNP in AL Amyloidosis
Preclinical Research Demonstrating a Direct Relationship Between Misfolded Light Chain Toxicity and NT-proBNP Production Clinical Outcomes Research Showing a Correlation between NT-proBNP Response and Health-related Quality of Life Data Presented at Heart Failure Society of Ame
Read more →PRTAProthena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting
Preclinical Research Demonstrating a Relationship Between Amyloid Light Chain Toxicity and NT-proBNP Production Clinical Outcomes Research Showing a Correlation between NT-proBNP and Health-related Quality of Life DUBLIN, Ireland, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Prothena Corp
Read more →PRTAProthena Reports Second Quarter 2017 Financial Results and Provides R&D Update Net cash used in operating and investing activities was $36.3 million in the second quarter and $76.5 million for the first six months of 201
Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update DUBLIN, Ireland - August 8, 2017 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immu
Read more →PRTAProthena to Report Second Quarter 2017 Financial Results on August 8
DUBLIN, Ireland, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the second quar
Read more →PRTAProthena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson’s Disease
First potentially disease-modifying anti-alpha-synuclein antibody to be evaluated for efficacy in patients with Parkinson’s disease Prothena to receive $30 million milestone payment under collaboration agreement with Roche DUBLIN, Ireland, July 05, 2017 (GLOBE NEWSWIRE) -- Prot
Read more →PRTAProthena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer
DUBLIN, Ireland, June 12, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Wagner Zago, PhD
Read more →PRTAProthena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer
DUBLIN, Ireland, May 16, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Sarah Noonberg, M
Read more →PRTAProthena Reports First Quarter 2017 Financial Results and Provides R&D Update Net cash used in operating and investing activities was $40.2 million in the first quarter; quarter-end cash and restricted cash position of $
Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update DUBLIN, Ireland - May 9, 2017 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunoth
Read more →PRTAProthena to Report First Quarter 2017 Financial Results on May 9
DUBLIN, Ireland, May 02, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the first quarte
Read more →PRTAProthena to Participate in the Deutsche Bank 42nd Annual Health Care Conference
DUBLIN, Ireland, April 26, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior managem
Read more →PRTAProthena Announces Pricing of Public Offering of 2,700,000 Ordinary Shares
DUBLIN, Ireland, March 03, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that it has sold 2,700,000 of its
Read more →PRTAProthena Announces Public Offering of Ordinary Shares
DUBLIN, Ireland, March 02, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that it has commenced a registered
Read more →PRTAProthena Reports Fourth Quarter and Full Year 2016 Financial Results, and Provides Financial Guidance and R&D Update Net cash used in operating and investing activities was $41.1 million in the fourth quarter and $133.9
Prothena Reports Fourth Quarter and Full Year 2016 Financial Results, and Provides Financial Guidance and R&D Update DUBLIN, Ireland - Feb. 14, 2017 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and co
Read more →PRTAProthena to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
DUBLIN, Ireland, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior manageme
Read more →PRTAProthena to Report Fourth Quarter and Full Year 2016 Financial Results and Host Webcast Conference Call on February 14
DUBLIN, Ireland, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quar
Read more →PRTAProthena to Participate in the J.P. Morgan Healthcare Conference
DUBLIN, Ireland, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior manageme
Read more →PRTAProthena Announces Appointment of Chief Regulatory Officer
DUBLIN, Ireland, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Carol D. Karp as
Read more →PRTAProthena Reports Results from Phase 1b Study of PRX002 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease All dose levels of PRX002
Prothena Reports Results from Phase 1b Study of PRX002 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease DUBLIN, Ireland, November 9, 2016 - Prothena Corporation plc (Nasdaq:PRTA), a late-st
Read more →PRTAProthena Reports Third Quarter 2016 Financial Results and Provides R&D Update Net cash used in operating and investing activities was $39.1 million in the third quarter and $96.8 million for the first nine months of 2016
Prothena Reports Third Quarter 2016 Financial Results and Provides R&D Update DUBLIN, Ireland - Nov. 1, 2016 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunot
Read more →PRTAProthena to Report Third Quarter 2016 Financial Results on November 1
DUBLIN, Ireland, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the third quart
Read more →PRTAProthena Announces Appointment of Dr. Gene G. Kinney as President, Chief Executive Officer and Director
DUBLIN, Ireland, Oct. 03, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that Gene Kinney, PhD has been appo
Read more →PRTAIn Memoriam - Friend, Scientific Innovator and Leader Dr. Dale B. Schenk has Passed Away
In Memoriam - Friend, Scientific Innovator and Leader Dr. Dale B. Schenk has Passed Away DUBLIN, Ireland, Sept. 30, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), announced today that its Co-founder, President and Chief Executive Officer, Dr. Dale B. Schenk, pa
Read more →PRTAProthena Outlines Phase 2 Development Strategy for PRX003
Investor conference call and webcast planned today at 4:30 PM ET DUBLIN, Ireland, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein i
Read more →PRTAProthena Announces President and CEO Dr. Dale B. Schenk to Take Medical Leave
DUBLIN, Ireland, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that its President and Chief Exec
Read more →PRTAProthena Announces President and CEO Dr.
Prothena Announces President and CEO Dr. Dale B. Schenk to Take Medical Leave DUBLIN, Ireland, Sept. 26, 2016 -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immu
Read more →PRTAProthena to Host Update on PRX003 Phase 2 Development Strategy
DUBLIN, Ireland, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that members of its management te
Read more →PRTAProthena Announces Appointment of Gene G. Kinney as Chief Operating Officer
DUBLIN, Ireland, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced the promotion of Gene G. Kinney,
Read more →PRTAProthena to Participate in Upcoming September Investor Conferences
DUBLIN, Ireland, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that members of its senior managem
Read more →PRTAProthena Reports Second Quarter 2016 Financial Results; Provides R&D Update Net cash used in operating and investing activities was $32.3 million in the second quarter and $57.7 million for the first six months of 2016;
Prothena Reports Second Quarter 2016 Financial Results; Provides R&D Update DUBLIN, Ireland - Aug. 2, 2016 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunothe
Read more →PRTAProthena to Participate in Cantor Fitzgerald’s 2nd Annual Healthcare Conference
DUBLIN, Ireland, July 06, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior manageme
Read more →PRTAProthena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis New data from Phase 1/2 dose-escalation (n=27) and expansion
Prothena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis DUBLIN, Ireland, July 5, 2016 Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focu
Read more →PRTAProthena to Present at 15th International Symposium on Amyloidosis Showcasing Broad Commitment to Advancing New Therapies for Systemic Amyloidoses
New clinical data to be presented from Phase 1/2 dose-escalation and expansion trial of NEOD001 for the potential treatment of AL amyloidosis Presentations to highlight data from clinical, preclinical and quality-of-life studies Investor webcast planned for July 5, 2016 at 10:3
Read more →PRTAProthena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases
All doses of PRX003 found to be safe and well tolerated, meeting the primary objective of the Phase 1 single ascending dose study in healthy volunteers Neutralization of Th17 cells of greater than 95 percent and statistically significant dose-dependent duration of MCAM downregul
Read more →PRTAProthena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis
New clinical data to be presented from expansion cohort of Phase 1/2 trial of NEOD001 for the potential treatment of AL amyloidosis Additional presentations to highlight data from preclinical and quality of life studies showcases commitment to advancing new therapies for multipl
Read more →PRTAProthena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st Congress
DUBLIN, Ireland, May 19, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that data from multiple quality of l
Read more →PRTAProthena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases, at EULAR 2016
DUBLIN, Ireland, May 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from its Phase 1
Read more →PRTAProthena Reports First Quarter 2016 Financial Results and Provides R&D Update Net cash used in operating and investing activities was $25.4 million in the first quarter; strong quarter-end cash position of $474.3 million
Prothena Reports First Quarter 2016 Financial Results and Provides R&D Update DUBLIN, Ireland - May 3, 2016 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunoth
Read more →PRTAProthena to Present Preclinical Data for PRX003 at 2016 AAAAI Annual Meeting
DUBLIN, Ireland, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that preclinical data from its PRX0
Read more →PRTAProthena Announces Appointment of Chief Commercial Officer
DUBLIN, Ireland, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of David B. McNinch
Read more →PRTAProthena Reports Fourth Quarter and Full Year 2015 Financial Results; Provides Financial Guidance and R&D Update
Prothena Reports Fourth Quarter and Full Year 2015 Financial Results; Provides Financial Guidance and R&D Update DUBLIN, Ireland - February 18, 2016 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and co
Read more →PRTAProthena to Report Fourth Quarter and Full Year 2015 Financial Results and Host Webcast Conference Call on February 18
DUBLIN, Ireland, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quar
Read more →PRTAProthena to Participate in BIO CEO & Investor and Leerink Partners Healthcare Conferences
DUBLIN, Ireland, Feb. 01, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior manageme
Read more →PRTAProthena Announces Pricing of Public Offering of 2,250,000 Ordinary Shares
DUBLIN, Ireland, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it priced an underwritten publ
Read more →PRTAProthena to Participate in Oppenheimer and RBC Capital Markets Healthcare Investor Conferences
DUBLIN, Ireland., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior managem
Read more →PRTAProthena to Present New Preclinical Data for NEOD001 at 57th Annual American Society of Hematology Meeting
DUBLIN, Ireland, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that new preclinical data related t
Read more →PRTAProthena to Present at the 2015 Credit Suisse Healthcare Conference on November 10
DUBLIN, Nov. 04, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of the senior management team w
Read more →PRTAProthena Reports Third Quarter 2015 Financial Results and Provides R&D Update Net cash used in operating activities was $16.9 million in the third quarter and $42.8 million for first nine months of 2015; quarter-end cash
Prothena Reports Third Quarter 2015 Financial Results and Provides R&D Update DUBLIN, Ireland - November 2, 2015 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein imm
Read more →PRTAProthena to Initiate PRONTO, a Global Trial of NEOD001 in Patients with AL Amyloidosis with Primary Endpoint of Cardiac Response Accelerates Development Timeline and Potential Path to Patients Prothena to Host Investor C
Prothena to Initiate PRONTO, a Global Trial of NEOD001 in Patients with AL Amyloidosis with Primary Endpoint of Cardiac Response DUBLIN, Ireland - October 15, 2015 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, de
Read more →PRTAProthena to Present at Ladenburg Thalmann 2015 Healthcare Conference on September 29
DUBLIN, Ireland, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of the senior managem
Read more →PRTAProthena Reports Second Quarter 2015 Financial Results and Provides R&D Update Net cash used in operating activities was $11.1 million in the second quarter and $25.9 million for first six months of 2015; completion of s
Prothena Reports Second Quarter 2015 Financial Results and Provides R&D Update DUBLIN, Ireland - August 4, 2015 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immu
Read more →PRTAProthena Announces Addition of Seasoned Executive to Board of Directors
Prothena Announces Addition of Seasoned Executive to Board of Directors DUBLIN, Ireland - June 29, 2015 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherap
Read more →PRTAProthena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease
PRX002 was Safe and Well Tolerated; Phase 1 Single Ascending Dose Study Objectives Met Dose- and Time-Dependent, Statistically Significant Reduction in Free Serum Alpha-Synuclein within One Hour of PRX002 Administration Data Presented in Late Breaking Poster Session at 19th Int
Read more →PRTAProthena to Present at JMP Securities Life Science Conference 2015 on June 23
DUBLIN, Ireland, June 16, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that members of the senior m
Read more →PRTAProthena's NEOD001 Protein Immunotherapy Clinical Data Highlighted in Oral Presentation at the 20th Congress of the European Hematology Association
DUBLIN, Ireland, June 12, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that Dr. Michaela Liedtke of
Read more →PRTAProthena Announces First Human Dosed in Phase 1 Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases
DUBLIN, Ireland, June 9, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced the successful first human do
Read more →PRTAProthena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders
Investor Conference Call and Webcast to be Held Wednesday, June 17, 2015 at 5:30 p.m. EDT DUBLIN, Ireland, June 8, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercializa
Read more →PRTAProthena Presents Compelling New Data From Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis at 2015 ASCO Annual Meeting
Positive NEOD001 Phase 1/2 Results Further Support the Design of The VITAL Amyloidosis Study, a Global Phase 3 Registrational Trial Increase in Best Response Rate to 60% in 15 Renal-Evaluable Patients Increase in Best Response Rate to 57% in 14 Cardiac-Evaluable Patients Resul
Read more →PRTAProthena Announces Presentation of Clinical Data From the Ongoing Phase 1/2 NEOD001 Study and Systemic Amyloidosis Patient Survey Results at 20th Congress of the European Hematology Association
DUBLIN, Ireland, May 21, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that Dr. Michaela Liedtke wil
Read more →PRTAProthena to Present Updated Clinical Data From Ongoing Phase 1/2 Study of NEOD001 at 2015 ASCO Annual Meeting
Investor Conference Call and Webcast to be Held Tuesday, June 2, 2015 at 3:00 p.m. EDT DUBLIN, Ireland, May 13, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercializatio
Read more →PRTAProthena Reports First Quarter 2015 Financial Results and Provides R&D Update Net cash used in operating activities was $14.7 million in the first quarter; net proceeds of $131.4 million raised through April 2015 public
Prothena Reports First Quarter 2015 Financial Results and Provides R&D Update DUBLIN, Ireland - May 5, 2015 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunoth
Read more →PRTAProthena to Present at Upcoming Investor Healthcare Conferences
DUBLIN, Ireland, April 28, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that members of the senior
Read more →PRTAProthena Announces Pricing of Public Offering of 3,300,000 Ordinary Shares
DUBLIN, Ireland, April 8, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, announced today that it priced an underwritt
Read more →PRTAProthena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of PRX002, a Novel Protein Immunotherapy for Parkinson's Disease
All Doses of PRX002 Found to be Safe and Well Tolerated, Meeting Primary Objective of Phase 1 Single Ascending Dose Study Results of Study Demonstrate Rapid and Dose-Dependent Reduction of Free Serum Alpha-Synuclein, Potential Disease-Causing Protein in Parkinson's Disease DUBL
Read more →PRTAProthena Reports Fourth Quarter and Full Year 2014 Financial Results and Provides 2015 Financial Guidance and R&D Update Net cash used in operating activities was $12.5 million in the fourth quarter and $0.7 million for
Prothena Reports Fourth Quarter and Full Year 2014 Financial Results and Provides 2015 Financial Guidance and R&D Update DUBLIN, Ireland - March 5, 2015 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development an
Read more →PRTAProthena to Report Fourth Quarter and Full Year 2014 Financial Results and Host Webcast and Conference Call on March 5
DUBLIN, Ireland, Feb. 19, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, announced today that it will report its four
Read more →PRTAProthena to Present at the 2015 RBC Capital Markets' Healthcare Conference in New York on February 25
DUBLIN, Ireland, Feb. 18, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, announced today that Gene Kinney, PhD, the C
Read more →PRTAProthena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of Patients with AL Amyloidosis First Investigational Immunotherapy for AL Amyloidosis to Receive FDA Fast Track Designati
Prothena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of Patients with AL Amyloidosis DUBLIN, Ireland - December 15, 2014 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, d
Read more →PRTAProthena to Present at the Oppenheimer 25th Annual Healthcare Conference in New York
DUBLIN, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve amyloid or cell adhesi
Read more →PRTAProthena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients with AL Amyloidosis New and Updated Results Show 50% Response Rate in 14 Cardiac-
Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients with AL Amyloidosis DUBLIN, Ireland - December 2, 2014 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company
Read more →PRTAProthena Reports Third Quarter 2014 Financial Results and R&D Progress Net cash used in operating activities was $12.3 million in the third quarter, while quarter-end cash position of $306.2 million provides solid runway
Prothena Reports Third Quarter 2014 Financial Results and R&D Progress DUBLIN, Ireland - November 3, 2014 - Prothena Corporation plc (NASDAQ:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the pote
Read more →PRTAProthena Announces Presentation at Federation of European Physiological Societies 2014 Congress
Data to be Presented by Dr. Timo Siepmann on the Discovery of a Potential New Non-Invasive Biomarker for Parkinson's Disease Results Extend Prior Research Confirming Skin Response (Goose Bump) Deficit in Patients With Early Stage Parkinson's Disease DUBLIN, Ireland, Aug. 26, 20
Read more →PRTAProthena Reports Second Quarter 2014 Financial Results and R&D Progress Completion of successful public equity offering netting $102.5 million and net cash provided by operating activities of $6.2 million in second quart
Prothena Reports Second Quarter 2014 Financial Results and R&D Progress DUBLIN, Ireland - August 4, 2014 - Prothena Corporation plc (NASDAQ:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the poten
Read more →PRTAProthena Announces Pricing of Public Offering of 4,750,000 Ordinary Shares
DUBLIN, Ireland, June 25, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfoldin
Read more →PRTAProthena to Present at the Jefferies 2014 Global Healthcare Conference in New York
DUBLIN, Ireland, May 27, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding
Read more →PRTAProthena Reports First Quarter 2014 Financial Results and Provides R&D Updates Encouraging cardiac biomarker responses from ongoing Phase 1 of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction pres
Prothena Reports First Quarter 2014 Financial Results and Provides R&D Updates DUBLIN, Ireland - May 5, 2014 - Prothena Corporation plc (NASDAQ:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the p
Read more →PRTAProthena to Host Webcast and Conference Call to Discuss Interim Phase 1 Data of Ongoing NEOD001 Study in Patients With AL Amyloidosis on May 2
DUBLIN, May 1, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell a
Read more →PRTAProthena Announces Appointment of Chief Legal Officer
DUBLIN, Ireland, April 30, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfoldi
Read more →PRTAProthena's NEOD001 Demonstrates Encouraging Cardiac Biomarker Responses in Ongoing Phase 1 Study in Patients With Immunoglobulin Light Chain (AL) Amyloidosis
NEOD001 appears generally safe, well-tolerated, has acceptable pharmacokinetic properties and no immunogenicity at studied dose levels No dose limiting toxicities have been observed Eight of nine evaluable patients with AL amyloidosis with cardiac involvement either achieved re
Read more →PRTAProthena Announces Clinical Data to be Presented at the International Symposium on Amyloidosis
Prothena Announces Clinical Data to be Presented at the International Symposium on Amyloidosis DUBLIN, Ireland - March 18, 2014 - Prothena Corporation plc (NASDAQ:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel a
Read more →PRTAProthena Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Research and Development Update
Prothena Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Research and Development Update DUBLIN, Ireland - March 6, 2014 - Prothena Corporation plc (NASDAQ:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercial
Read more →PRTAProthena Announces Appointment of Chief Business Officer
DUBLIN, Ireland, March 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfoldin
Read more →PRTAProthena to Report Fourth Quarter and Full Year 2013 Financial Results and Host Webcast and Conference Call on March 6
Prothena to participate in February investor healthcare conferences, February 24-25 DUBLIN, Ireland, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of no
Read more →PRTAProthena Announces Closing of Underwritten Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Ordinary Shares From Perrigo
DUBLIN, Ireland, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding
Read more →PRTAProthena Announces Pricing of Secondary Offering of Ordinary Shares by Perrigo
DUBLIN, Ireland, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfoldin
Read more →PRTAProthena Announces Proposed Secondary Offering of Ordinary Shares by Perrigo
DUBLIN, Ireland, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfoldin
Read more →PRTARegulation We anticipate that if we commercialize any products, the U.S. market will be our most important market. For this reason, the laws and regulations discussed below focus on the requirements applicable to biologi
We anticipate that if we commercialize any products, the U.S. market will be our most important market. For this reason, the laws and regulations discussed below focus on the requirements applicable to biologic products in the United States. Government Regulation Governmental
Read more →PRTAProthena to Receive $30 Million Upfront Payment from Roche Triggered by the Expiration of Hart-Scott-Rodino Waiting Period
DUBLIN, Ireland, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfoldin
Read more →PRTAProthena to be Added to NASDAQ Biotechnology Index and NASDAQ Global Select Market
DUBLIN, Ireland, Dec. 30, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of a broad range of diseases, today announ
Read more →PRTARoche and Prothena Enter into Worldwide Collaboration to Co-Develop and Co-Promote Antibodies for Treatment of Parkinson's Disease Prothena to receive up to $600 million, inclusive of upfront payment and near-term clinic
Roche and Prothena Enter into Worldwide Collaboration to Co-Develop and Co-Promote Antibodies for Treatment of Parkinson's Disease BASEL, Switzerland and DUBLIN, Ireland - December 11, 2013 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Prothena Corporation plc (NASDAQ:PRTA), announce
Read more →PRTAProthena Reports Third Quarter 2013 Financial Results
Prothena Reports Third Quarter 2013 Financial Results DUBLIN, Ireland - November 12, 2013 - Prothena Corporation plc (NASDAQ:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment
Read more →PRTAProthena Announces Research and Development Day and Webcast
DUBLIN, Ireland, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of a broad range of diseases, today announ
Read more →PRTAProthena Announces Pricing of Public Offering of 5,910,000 Ordinary Shares
DUBLIN, Ireland, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that it has priced an
Read more →PRTAPROTHENA REPORTS SECOND QUARTER 2013
PROTHENA REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS DUBLIN, Ireland August 12, 2013 Prothena Corporation plc (NASDAQ:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of dis
Read more →PRTAProthena Reports Second Quarter 2013 Financial Results
DUBLIN, Ireland, Aug. 12, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today reported financial result
Read more →PRTAProthena to Present at the Wedbush Securities Life Sciences Management Access Conference in New York
DUBLIN, Ireland, Aug. 7, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that Gene Kinney, PhD
Read more →PRTAPROTHENA
PROTHENA WELCOMES NEW DIRECTOR TO ITS BOARD DUBLIN, Ireland July 22, 2013 Prothena Corporation plc (NASDAQ:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today
Read more →PRTAProthena Welcomes New Director to Its Board
DUBLIN, Ireland, July 22, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the appointment
Read more →PRTAProthena to Present at the Eighth Annual JMP Securities Healthcare Conference in New York
DUBLIN, Ireland, July 1, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that Dale Schenk, PhD
Read more →PRTAProthena Shares to Be Added to Russell Global Index
DUBLIN, Ireland, June 17, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that the trading of i
Read more →PRTAProthena to Present at the Jefferies 2013 Global Healthcare Conference in New York
DUBLIN, Ireland, May 29, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that Dale Schenk, PhD
Read more →PRTAProthena Reports First Quarter Financial Results
DUBLIN, Ireland, May 14, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today reported financial result
Read more →PRTAPROTHENA REPORTS FIRST QUARTER FINANCIAL RESULTS Phase 1 clinical trial initiated in April for NEOD001 in AL amyloidosis patients
PROTHENA REPORTS FIRST QUARTER FINANCIAL RESULTS Phase 1 clinical trial initiated in April for NEOD001 in AL amyloidosis patients DUBLIN, Ireland May 14, 2013 Prothena Corporation plc. (NASDAQ:PRTA), a clinical stage biotechnology company focused on the discovery and developme
Read more →PRTAFirst Patient Dosed in Phase I Study of Prothena s Therapeutic Antibody for Treatment of AL Amyloidosis NEOD001 enters clinic with orphan designation and potential to meet significant unmet need
First Patient Dosed in Phase I Study of Prothena s Therapeutic Antibody for Treatment of AL NEOD001 enters clinic with orphan designation and potential to meet significant unmet need DUBLIN, Ireland, April 23, 2013 Prothena Corporation plc (NASDAQ:PRTA), a clinical stage biotec
Read more →PRTAto the Company s Current Report on Form 8-K filed with the Securities and Exchange Commission on
PROTHENA REPORTS FOURTH QUARTER AND FULL YEAR 2012 FINANCIAL RESULTS AND PROVIDES RESEARCH AND Company Advances Pipeline with Strong Capital Position Following 2012 Spin-Off NEOD001 to Enter Clinic in Early 2013 DUBLIN, Ireland, Mar. 28, 2013 Prothena Corporation plc (NASDAQ:P
Read more →PRTAProthena Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Research and Development Update
Company Advances Pipeline With Strong Capital Position Following 2012 Spin-Off NEOD001 to Enter Clinic in Early 2013 DUBLIN, Ireland, March 28, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of n
Read more →PRTAProthena Announces Appointments of Chief Medical Officer and Chief Financial Officer
DUBLIN, Ireland, March 25, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that two senior executives ha
Read more →PRTAProthena to Report Fourth Quarter and Full Year 2012 Financial Results and Host Webcast and Conference Call on March 28, 2013
DUBLIN, Ireland, March 21, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that it will report its fourt
Read more →PRTAto our Current Report on Form 8-K filed with the Securities and Exchange Commission on
Prothena Announces Appointment of Biotech Pioneer to Board of Directors Christopher S. Henney, PhD joins Prothena Board DUBLIN, Ireland, Mar. 19, 2013 - Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies
Read more →PRTAProthena Announces Appointment of Biotech Pioneer to Board of Directors
DUBLIN, Ireland, March 19, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the appointment of Christophe
Read more →PRTAProthena Achieves Orphan Drug Status in EU for Lead Program NEOD001
DUBLIN, Ireland, Feb. 27, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that the European Medicines Ag
Read more →PRTAProthena to Ring NASDAQ Stock Market Opening Bell
DUBLIN, Ireland, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that its President and Chief E
Read more →PRTAProthena Corporation plc [PRTA] to Ring The NASDAQ Stock Market Opening Bell
ADVISORY, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Prothena [PRTA], a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, will visit the NASDAQ MarketSite in Times Square. In honor of the occasion
Read more →PRTAProthena Announces Addition of Industry Veterans to Board of Directors
DUBLIN, Ireland, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the appointment of Richard T. C
Read more →PRTAProthena Begins Trading on NASDAQ Global Market Under Symbol "PRTA"
DUBLIN, Ireland, Dec. 21, 2012 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the successful completion of i
Read more →PRTAINFORMATION STATEMENT Prothena Corporation plc Ordinary Shares (par value $0.01 per share) This information statement is being furnished in connection with the separation of a substantial portion of the drug discovery bu
INFORMATION STATEMENT Prothena Corporation plc (par value $0.01 per share) statement is being furnished in connection with the separation of a substantial portion of the drug discovery business platform of Elan Corporation, plc ( Elan ), which we describe more specifically her
Read more →Competitive Position
How PRTA ranks across every disease it competes inCompetitive Position is a premium feature
See how PRTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial